Newron Pharmaceuticals announced on September 2 that it has completed screening toward enrollment in ENIGMA-TRS 1, its pivotal Phase 3 trial testing evenamide in treatment-resistant schizophrenia. Nearly a thousand patients have gone through screening, 411 have already been randomized into the trial, and the company expects to hit its 600-patient enrollment target by mid-October. That’s an operational milestone, not a result. The reason it’s worth attention now is what the drug is built to do, not what the screening numbers show.
A drug aimed at the one pathway current antipsychotics skip
Every antipsychotic approved today, from older drugs like haloperidol to newer ones like clozapine, works primarily by blocking dopamine receptors in the brain. Evenamide works differently. It blocks voltage-gated sodium channels, a different kind of cellular switch, and through that mechanism it calms down abnormal glutamate release without affecting the brain’s normal glutamate levels. Glutamate is a separate signaling chemical from dopamine, and a growing body of research points to glutamate dysfunction as a real contributor to why some schizophrenia patients don’t respond to dopamine-based treatment at all. If that research holds up, a drug working through this second pathway could help exactly the patients current antipsychotics have nothing left to offer.
Who the trial is testing the drug on
Treatment-resistant schizophrenia, TRS for short, describes patients who get little to no benefit from two different antipsychotics tried at adequate doses. It’s not a small group: an estimated 15 percent of schizophrenia patients meet this definition from the very onset of their illness, and by some estimates one-third to 50 percent of all schizophrenia patients eventually do. Evenamide isn’t being tested as a replacement for existing antipsychotics. It’s being tested as an add-on, taken alongside whatever a patient is already on, including clozapine, itself typically the last resort for TRS and a drug that requires regular blood monitoring because of its own serious side effect risks. A drug that could boost clozapine’s effect, or help patients who don’t respond even to clozapine, would be filling a gap nothing currently on the market addresses.
What the trial is designed to measure, and when
Patients entering the trial go through a 42-day screening period, during which a panel of three independent schizophrenia specialists confirms each patient meets treatment-resistance criteria before they’re randomized. Once enrolled, patients receive one of two evenamide doses or a placebo, on top of their existing antipsychotic, for a full year, though the primary result will come at week 12, measured using PANSS, the standard scale researchers use to rate schizophrenia symptom severity. Newron expects that first data readout in the first quarter of 2027.
What isn’t known yet
Nothing here confirms evenamide works. Newron points to earlier Phase 2 and Phase 3 studies as showing “significant and increasing efficacy,” but this release doesn’t include the specific numbers behind that claim, and a company’s own characterization of its earlier results is not the same as the pivotal trial’s own outcome, which hasn’t been generated yet. A strong enrollment pace is a real positive signal, it usually means investigators are motivated to participate, but it says nothing about whether the drug separates from placebo when the data comes in.
What to watch for in early 2027
When the 12-week results land, the single most important number will be how evenamide performs against placebo on PANSS specifically in patients already on clozapine, since that’s the subgroup with the least existing treatment options and the clearest test of whether this mechanism adds anything current care doesn’t already provide. This piece will be updated once that data is available.